Pediatric Brain Tumor Foundation
Working to eliminate the challenges of childhood brain tumors

Cure the kids! Give Now

Testing the Addition of Whole Brain Radiotherapy Using a Technique That Avoids the Hippocampus to Stereotactic Radiosurgery in People With Cancer That Has Spread to the Brain and Come Back in Other Areas of the Brain After Earlier Stereotactic Radiosurgery

Study Purpose

This phase III trial compares the effect of adding whole brain radiotherapy with hippocampal avoidance and memantine to stereotactic radiosurgery versus stereotactic radiosurgery alone in treating patients with cancer that has spread to the brain and come back in other areas of the brain after earlier stereotactic radiosurgery. Hippocampus avoidance during whole-brain radiation therapy decreases the amount of radiation that is delivered to the hippocampus, which is a brain structure that is important for memory. The medicine memantine is also often given with whole brain radiation therapy because it may decrease the risk of side effects of radiation on thinking and memory. Stereotactic radiosurgery delivers a high dose of radiation only to the small areas of cancer in the brain and avoids the surrounding normal brain tissue. Adding whole brain radiotherapy with hippocampal avoidance and memantine to stereotactic radiosurgery may be effective in shrinking or stabilizing cancer that has spread to the brain and returned in other areas of the brain after receiving stereotactic radiosurgery.

Recruitment Criteria

Accepts Healthy Volunteers

Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms

No
Study Type

An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.


An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes.


Searching Both is inclusive of interventional and observational studies.

Interventional
Eligible Ages 18 Years and Over
Gender All
More Inclusion & Exclusion Criteria

Inclusion Criteria:

  • - Patients must have developed their first or second distant brain relapse(s) at least 8 weeks after upfront SRS and within 21 days prior to randomization.
  • - Distant brain relapse lesions to be treated must measure =< 3.0 cm in maximal extent and total volume of distant brain relapses to be treated must measure < 30 mL on the contrast-enhanced diagnostic magnetic resonance imaging (MRI) brain scan obtained within 21 days prior to randomization.
  • - Distant brain relapse lesions must be diagnosed on MRI, which will include the following elements: - REQUIRED MRI ELEMENTS.
  • - Post gadolinium contrast-enhanced T1-weighted three-dimensional (3D) spoiled gradient (SPGR).
Acceptable 3D SPGR sequences include magnetization-prepared 3D gradient recalled echo (GRE) rapid gradient echo (MP-RAGE), turbo field echo (TFE) MRI, BRAVO (brain volume imaging) or 3D fast FE (field echo). The T1-weighted 3D scan should use the smallest possible axial slice thickness, not to exceed 1.5 mm.
  • - Pre-contrast T1 weighted imaging (3D imaging sequence strongly encouraged) - A minimum of one axial T2 fluid attenuated inversion recovery (FLAIR) (preferred) or T2 sequence is required.
This can be acquired as a 2D or 3D image. If 2D, the images should be obtained in the axial plane.
  • - ADDITIONAL RECOMMENDATIONS.
  • - Recommendation is that an axial T2 FLAIR (preferred) sequence be performed instead of a T2 sequence.
  • - Recommendation is that that pre-contrast 3D T1 be performed with the same parameters as the post-contrast 3D T1.
  • - Recommendation is that imaging be performed on a 3 Tesla (3T) MRI.
  • - Recommendation is that the study participants be scanned on the same MRI instrument at each time point.
  • - Recommendation is that if additional sequences are obtained, these should meet the criteria outlined in Kaufmann et al.
, 2020.
  • - If additional sequences are obtained, total imaging time should not exceed 60 minutes.
  • - Brain metastasis velocity (BMV) since upfront SRS must be >= 4 brain metastases/year.
  • - The patient or a legally authorized representative must provide study-specific informed consent prior to study entry.
  • - Pathologically (histologically or cytologically) proven diagnosis of non-small cell lung cancer, melanoma, breast cancer, renal cell carcinoma, or gastrointestinal cancer within 10 years prior to randomization.
If the original histologic proof of malignancy is greater than 10 years, then pathological (i.e., more recent) confirmation is required (e.g., from a systemic metastasis or brain metastasis)
  • - Other histologies are not permitted.
  • - History and physical examination within 28 days prior to randomization.
  • - Karnofsky performance status of >= 70 within 28 days prior to randomization.
  • - Calculated creatinine clearance (CrCl) >= 30 ml/min (within 28 days prior to randomization) - Blood urea nitrogen (BUN) within 1.5 times the institutional upper limit of normal (ULN) (e.g., if the ULN is 20 mg/dL, then BUN up to 30 mg/dL is permitted) (within 28 days prior to randomization) - Negative urine or serum pregnancy test (in women of childbearing potential) within 14 days prior to randomization.

Exclusion Criteria:

  • - Prior WBRT or prophylactic cranial irradiation.
  • - Local relapse of metastasis previously treated with upfront SRS (i.e., relapse outside previously SRS-treated metastases is allowed) - Brain metastases from primary germ cell tumor, small cell carcinoma, or lymphoma.
  • - Definitive leptomeningeal metastasis.
  • - Planned cytotoxic chemotherapy on the same day as SRS or HA-WBRT; concurrent immunotherapy is permitted.
  • - Radiographic evidence of enlargement or other architectural distortion of the lateral ventricles, including placement of external ventricular drain or ventriculoperitoneal shunt.
  • - Known history of demyelinating disease such as multiple sclerosis.
  • - Inability to swallow pills.
  • - Contraindication to MR imaging such as non-MR conditional implanted metal devices or unknown metallic foreign bodies, or contraindication to gadolinium contrast administration during MR imaging, such as anaphylactic allergy that cannot be adequately addressed with pre-contrast medications or acute kidney injury.
  • - Contraindications to memantine, including: - Allergy, including prior allergic reaction to memantine.
  • - Intractable seizures on adequate anticonvulsive therapy-more than 1 seizure per month for the past 2 months.
  • - Current use of N-methyl-D-aspartate (NMDA) agonist.
  • - Current alcohol or drug abuse, which can exacerbate lethargy/dizziness with memantine.
  • - Severe, active co-morbidity defined as follows: - Unstable angina and/or congestive heart failure requiring hospitalization within the last 6 months.
  • - Transmural myocardial infarction within the last 6 months.
  • - Acute bacterial or fungal infection requiring intravenous antibiotics at the time of randomization.
  • - Chronic obstructive pulmonary disease exacerbation or other acute respiratory illness precluding study therapy at the time of randomization.
  • - Severe hepatic disease defined as a diagnosis of Child-Pugh class B or C hepatic disease.
  • - Renal tubular acidosis or metabolic acidosis.
  • - Human immunodeficiency virus (HIV) positive with CD4 count < 200 cells/microliter.
Note that patients who are HIV positive are eligible, provided they are under treatment with highly active antiretroviral therapy (HAART) and have a CD4 count >= 200 cells/microliter within 30 days prior to randomization. Note also that HIV testing is not required for eligibility for this protocol. - Pregnant or lactating women, or women of childbearing potential and men who are sexually active and not willing/able to use medically acceptable forms of contraception; this exclusion is necessary because the medication and radiation involved in this study has unknown effects on the unborn fetus

Trial Details

Trial ID:

This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries.

NCT04588246
Phase

Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans.

Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data.

Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs.

Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use.

Phase 3
Lead Sponsor

The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data.

NRG Oncology
Principal Investigator

The person who is responsible for the scientific and technical direction of the entire clinical study.

Vinai Gondi
Principal Investigator Affiliation NRG Oncology
Agency Class

Category of organization(s) involved as sponsor (and collaborator) supporting the trial.

Other, NIH
Overall Status Recruiting
Countries United States
Conditions

The disease, disorder, syndrome, illness, or injury that is being studied.

Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Metastatic Digestive System Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Neoplasm in the Brain, Metastatic Melanoma, Metastatic Renal Cell Carcinoma, Prognostic Stage IV Breast Cancer AJCC v8, Recurrent Brain Neoplasm, Stage IV Lung Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Additional Details

PRIMARY OBJECTIVE:

  • I. To determine if salvage stereotactic radiosurgery (SRS) plus whole brain radiotherapy with hippocampal avoidance (HA-WBRT) in patients with brain metastasis velocity >= 4 new brain metastases/year at time of first or second distant brain failure following upfront SRS prolongs time to neurologic death as compared to salvage SRS alone.
SECONDARY OBJECTIVES:
  • I. To determine if salvage SRS + HA-WBRT in patients with brain metastasis velocity >= 4 new brain metastases/year at time of first or second distant brain failure following upfront SRS prolongs overall survival as compared to salvage SRS alone.
  • II. To evaluate if salvage SRS + HA-WBRT in patients with brain metastasis velocity >= 4 new brain metastases/year at time of first or second distant brain failure following upfront SRS prolongs intracranial progression-free survival as compared to salvage SRS alone.
  • III. To evaluate if salvage SRS + HA-WBRT in patients with brain metastasis velocity >= 4 new brain metastases/year at time of first or second distant brain failure following upfront SRS improves brain metastasis velocity at subsequent relapse as compared to salvage SRS alone.
  • IV. To assess perceived difficulties in cognitive abilities, symptom burden and health status after salvage SRS + HA-WBRT, as compared to salvage SRS alone, in patients with brain metastasis velocity >= 4 new brain metastases/year at time of first or second distant brain failure following upfront SRS.
  • V. To compare neurocognitive function outcomes following salvage SRS + HA-WBRT, as compared to salvage SRS alone, in patients with brain metastasis velocity >= 4 new brain metastases/year at time of first or second distant brain failure following upfront SRS.
  • VI. To tabulate and descriptively compare the adverse events associated with the interventions.
  • VII. To tabulate and descriptively compare the number of salvage procedures used to manage recurrent intracranial disease following the interventions.
EXPLORATORY OBJECTIVES:
  • I. To collect serum, plasma, and whole blood for translational research analyses.
  • II. To collect baseline and all follow-up magnetic resonance (MR) imaging for hippocampal volume, memory center substructures, axial T2 volumes, and quantitative texture analysis.
  • III. To collect baseline and follow-up MR imaging to extract whole brain volume, white matter volume and volume of metastatic disease to correlate with cognitive change at 4 months.
  • IV. To evaluate dose-volume histogram parameters to correlate with radiation toxicity.
  • V. To assess in patients receiving immunotherapy or targeted therapy, if salvage SRS + HA-WBRT in patients with brain metastasis velocity >= 4 new brain metastases/year at time of first or second distant brain failure following upfront SRS improves brain metastasis velocity and/or overall survival at subsequent relapse as compared to salvage SRS.
  • VI. To compare the estimated cost of brain-related therapies and quality-adjusted life years in patients who receive salvage SRS + HA-WBRT, as compared to salvage SRS alone, in patients with metastasis velocity >= 4 new brain metastases/year at time of first or second distant brain failure following upfront SRS.
OUTLINE: Patients are randomized to 1 of 2 arms. ARM I: Patients undergo HA-WBRT daily (5 times weekly) for 2 weeks for a total of 10 fractions in the absence of disease progression or unacceptable toxicity. Within 1 week prior to or following HA-WBRT, patients undergo salvage SRS. Prior to HA-WBRT or no later than the 4th treatment, patients also receive memantine orally (PO) once daily (QD) or twice daily (BID) for 24 weeks in the absence of disease progression or unacceptable toxicity. ARM II: Patients undergo salvage SRS. After completion of study treatment, patients are followed up every 2-3 months for at least 1 year.

Arms & Interventions

Arms

Experimental: Arm I (salvage SRS, memantine, HA-WBRT)

Patients undergo HA-WBRT daily (5 times weekly) for 2 weeks for a total of 10 fractions in the absence of disease progression or unacceptable toxicity. Within 1 week prior to or following HA-WBRT, patients undergo salvage SRS. Prior to HA-WBRT or no later than the 4th treatment, patients also receive memantine PO QD or BID for 24 weeks in the absence of disease progression or unacceptable toxicity.

Active Comparator: Arm II (salvage SRS)

Patients undergo salvage SRS.

Interventions

Drug: - Memantine

Given PO

Other: - Quality-of-Life Assessment

Ancillary studies

Other: - Questionnaire Administration

Ancillary studies

Radiation: - Stereotactic Radiosurgery

Undergo salvage SRS

Radiation: - Whole-Brain Radiotherapy

Undergo HA-WBRT

Contact a Trial Team

If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.

Tucson, Arizona

Status

Recruiting

Address

Banner University Medical Center - Tucson

Tucson, Arizona, 85719

Site Contact

Site Public Contact

[email protected]

Tucson, Arizona

Status

Recruiting

Address

University of Arizona Cancer Center-North Campus

Tucson, Arizona, 85719

Site Contact

Site Public Contact

[email protected]

City of Hope Corona, Corona, California

Status

Recruiting

Address

City of Hope Corona

Corona, California, 92879

Site Contact

Site Public Contact

[email protected]

800-826-4673

City of Hope Comprehensive Cancer Center, Duarte, California

Status

Recruiting

Address

City of Hope Comprehensive Cancer Center

Duarte, California, 91010

Site Contact

Site Public Contact

[email protected]

800-826-4673

City of Hope at Irvine Lennar, Irvine, California

Status

Recruiting

Address

City of Hope at Irvine Lennar

Irvine, California, 92618

Site Contact

Site Public Contact

877-467-3411

City of Hope Antelope Valley, Lancaster, California

Status

Recruiting

Address

City of Hope Antelope Valley

Lancaster, California, 93534

Site Contact

Site Public Contact

[email protected]

800-826-4673

Roseville, California

Status

Recruiting

Address

Sutter Cancer Centers Radiation Oncology Services-Roseville

Roseville, California, 95661

Site Contact

Site Public Contact

[email protected]

Sutter Roseville Medical Center, Roseville, California

Status

Recruiting

Address

Sutter Roseville Medical Center

Roseville, California, 95661

Site Contact

Site Public Contact

[email protected]

Sutter Medical Center Sacramento, Sacramento, California

Status

Recruiting

Address

Sutter Medical Center Sacramento

Sacramento, California, 95816

Site Contact

Site Public Contact

[email protected]

City of Hope South Pasadena, South Pasadena, California

Status

Recruiting

Address

City of Hope South Pasadena

South Pasadena, California, 91030

Site Contact

Site Public Contact

[email protected]

800-826-4673

City of Hope South Bay, Torrance, California

Status

Recruiting

Address

City of Hope South Bay

Torrance, California, 90503

Site Contact

Site Public Contact

877-467-3411

City of Hope Upland, Upland, California

Status

Recruiting

Address

City of Hope Upland

Upland, California, 91786

Site Contact

Site Public Contact

[email protected]

800-826-4673

Newark, Delaware

Status

Suspended

Address

Delaware Clinical and Laboratory Physicians PA

Newark, Delaware, 19713

Helen F Graham Cancer Center, Newark, Delaware

Status

Recruiting

Address

Helen F Graham Cancer Center

Newark, Delaware, 19713

Site Contact

Site Public Contact

[email protected]

302-623-4450

Newark, Delaware

Status

Recruiting

Address

Medical Oncology Hematology Consultants PA

Newark, Delaware, 19713

Site Contact

Site Public Contact

[email protected]

302-623-4450

Newark, Delaware

Status

Recruiting

Address

Christiana Care Health System-Christiana Hospital

Newark, Delaware, 19718

Site Contact

Site Public Contact

[email protected]

302-623-4450

Coral Gables, Florida

Status

Active, not recruiting

Address

UM Sylvester Comprehensive Cancer Center at Coral Gables

Coral Gables, Florida, 33146

Deerfield Beach, Florida

Status

Active, not recruiting

Address

UM Sylvester Comprehensive Cancer Center at Deerfield Beach

Deerfield Beach, Florida, 33442

Mayo Clinic in Florida, Jacksonville, Florida

Status

Completed

Address

Mayo Clinic in Florida

Jacksonville, Florida, 32224-9980

Miami, Florida

Status

Active, not recruiting

Address

University of Miami Miller School of Medicine-Sylvester Cancer Center

Miami, Florida, 33136

Memorial Hospital West, Pembroke Pines, Florida

Status

Recruiting

Address

Memorial Hospital West

Pembroke Pines, Florida, 33028

Site Contact

Site Public Contact

954-265-4325

Northwestern University, Chicago, Illinois

Status

Recruiting

Address

Northwestern University

Chicago, Illinois, 60611

Site Contact

Site Public Contact

[email protected]

312-695-1301

Rush University Medical Center, Chicago, Illinois

Status

Recruiting

Address

Rush University Medical Center

Chicago, Illinois, 60612

Site Contact

Site Public Contact

[email protected]

312-942-5498

Chicago, Illinois

Status

Recruiting

Address

University of Chicago Comprehensive Cancer Center

Chicago, Illinois, 60637

Site Contact

Site Public Contact

[email protected]

773-702-8222

Carle at The Riverfront, Danville, Illinois

Status

Recruiting

Address

Carle at The Riverfront

Danville, Illinois, 61832

Site Contact

Site Public Contact

[email protected]

800-446-5532

DeKalb, Illinois

Status

Recruiting

Address

Northwestern Medicine Cancer Center Kishwaukee

DeKalb, Illinois, 60115

Site Contact

Site Public Contact

[email protected]

630-352-5360

Carle Physician Group-Effingham, Effingham, Illinois

Status

Recruiting

Address

Carle Physician Group-Effingham

Effingham, Illinois, 62401

Site Contact

Site Public Contact

[email protected]

800-446-5532

Geneva, Illinois

Status

Recruiting

Address

Northwestern Medicine Cancer Center Delnor

Geneva, Illinois, 60134

Site Contact

Site Public Contact

[email protected]

630-352-5360

Carle Physician Group-Mattoon/Charleston, Mattoon, Illinois

Status

Recruiting

Address

Carle Physician Group-Mattoon/Charleston

Mattoon, Illinois, 61938

Site Contact

Site Public Contact

[email protected]

800-446-5532

Carle Cancer Center, Urbana, Illinois

Status

Recruiting

Address

Carle Cancer Center

Urbana, Illinois, 61801

Site Contact

Site Public Contact

[email protected]

800-446-5532

The Carle Foundation Hospital, Urbana, Illinois

Status

Recruiting

Address

The Carle Foundation Hospital

Urbana, Illinois, 61801

Site Contact

Site Public Contact

[email protected]

800-446-5532

Warrenville, Illinois

Status

Recruiting

Address

Northwestern Medicine Cancer Center Warrenville

Warrenville, Illinois, 60555

Site Contact

Site Public Contact

[email protected]

630-352-5360

Baltimore, Maryland

Status

Recruiting

Address

University of Maryland/Greenebaum Cancer Center

Baltimore, Maryland, 21201

Site Contact

Site Public Contact

800-888-8823

Baltimore, Maryland

Status

Recruiting

Address

MedStar Franklin Square Medical Center/Weinberg Cancer Institute

Baltimore, Maryland, 21237

Site Contact

Site Public Contact

443-777-7364

UM Upper Chesapeake Medical Center, Bel Air, Maryland

Status

Recruiting

Address

UM Upper Chesapeake Medical Center

Bel Air, Maryland, 21014

Site Contact

Site Public Contact

443-643-3010

Columbia, Maryland

Status

Recruiting

Address

Central Maryland Radiation Oncology in Howard County

Columbia, Maryland, 21044

Site Contact

Site Public Contact

443-546-1300

Glen Burnie, Maryland

Status

Recruiting

Address

UM Baltimore Washington Medical Center/Tate Cancer Center

Glen Burnie, Maryland, 21061

Site Contact

Site Public Contact

410-553-8100

Tufts Medical Center, Boston, Massachusetts

Status

Recruiting

Address

Tufts Medical Center

Boston, Massachusetts, 02111

Site Contact

Site Public Contact

[email protected]

617-636-5000

Saint Joseph Mercy Hospital, Ann Arbor, Michigan

Status

Suspended

Address

Saint Joseph Mercy Hospital

Ann Arbor, Michigan, 48106

Brighton, Michigan

Status

Suspended

Address

Trinity Health IHA Medical Group Hematology Oncology - Brighton

Brighton, Michigan, 48114

Saint Joseph Mercy Chelsea, Chelsea, Michigan

Status

Suspended

Address

Saint Joseph Mercy Chelsea

Chelsea, Michigan, 48118

Chelsea, Michigan

Status

Suspended

Address

Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital

Chelsea, Michigan, 48118

Ypsilanti, Michigan

Status

Suspended

Address

Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus

Ypsilanti, Michigan, 48197

University of Mississippi Medical Center, Jackson, Mississippi

Status

Active, not recruiting

Address

University of Mississippi Medical Center

Jackson, Mississippi, 39216

Creve Coeur, Missouri

Status

Recruiting

Address

Siteman Cancer Center at West County Hospital

Creve Coeur, Missouri, 63141

Site Contact

Site Public Contact

[email protected]

800-600-3606

Washington University School of Medicine, Saint Louis, Missouri

Status

Recruiting

Address

Washington University School of Medicine

Saint Louis, Missouri, 63110

Site Contact

Site Public Contact

[email protected]

800-600-3606

Siteman Cancer Center-South County, Saint Louis, Missouri

Status

Recruiting

Address

Siteman Cancer Center-South County

Saint Louis, Missouri, 63129

Site Contact

Site Public Contact

[email protected]

800-600-3606

Saint Louis, Missouri

Status

Recruiting

Address

Siteman Cancer Center at Christian Hospital

Saint Louis, Missouri, 63136

Site Contact

Site Public Contact

[email protected]

800-600-3606

Saint Peters, Missouri

Status

Recruiting

Address

Siteman Cancer Center at Saint Peters Hospital

Saint Peters, Missouri, 63376

Site Contact

Site Public Contact

[email protected]

800-600-3606

Lake Success, New York

Status

Recruiting

Address

Northwell Health/Center for Advanced Medicine

Lake Success, New York, 11042

Site Contact

Site Public Contact

516-734-8896

University of Rochester, Rochester, New York

Status

Recruiting

Address

University of Rochester

Rochester, New York, 14642

Site Contact

Site Public Contact

585-275-5830

Wake Forest University Health Sciences, Winston-Salem, North Carolina

Status

Recruiting

Address

Wake Forest University Health Sciences

Winston-Salem, North Carolina, 27157

Site Contact

Site Public Contact

336-713-6771

Sanford Bismarck Medical Center, Bismarck, North Dakota

Status

Recruiting

Address

Sanford Bismarck Medical Center

Bismarck, North Dakota, 58501

Site Contact

Site Public Contact

[email protected]

701-323-5760

Sanford Broadway Medical Center, Fargo, North Dakota

Status

Recruiting

Address

Sanford Broadway Medical Center

Fargo, North Dakota, 58122

Site Contact

Site Public Contact

[email protected]

701-323-5760

Sanford Roger Maris Cancer Center, Fargo, North Dakota

Status

Recruiting

Address

Sanford Roger Maris Cancer Center

Fargo, North Dakota, 58122

Site Contact

Site Public Contact

[email protected]

701-234-6161

Columbus, Ohio

Status

Recruiting

Address

Ohio State University Comprehensive Cancer Center

Columbus, Ohio, 43210

Site Contact

Site Public Contact

[email protected]

800-293-5066

Oklahoma City, Oklahoma

Status

Recruiting

Address

University of Oklahoma Health Sciences Center

Oklahoma City, Oklahoma, 73104

Site Contact

Site Public Contact

[email protected]

405-271-8777

Chadds Ford, Pennsylvania

Status

Recruiting

Address

Christiana Care Health System-Concord Health Center

Chadds Ford, Pennsylvania, 19317

Site Contact

Site Public Contact

[email protected]

302-623-4450

Geisinger Medical Center, Danville, Pennsylvania

Status

Recruiting

Address

Geisinger Medical Center

Danville, Pennsylvania, 17822

Site Contact

Site Public Contact

[email protected]

570-271-5251

Greensburg, Pennsylvania

Status

Active, not recruiting

Address

UPMC Cancer Centers - Arnold Palmer Pavilion

Greensburg, Pennsylvania, 15601

Geisinger Medical Oncology-Lewisburg, Lewisburg, Pennsylvania

Status

Recruiting

Address

Geisinger Medical Oncology-Lewisburg

Lewisburg, Pennsylvania, 17837

Site Contact

Site Public Contact

[email protected]

570-374-8555

Riddle Memorial Hospital, Media, Pennsylvania

Status

Suspended

Address

Riddle Memorial Hospital

Media, Pennsylvania, 19063

Thomas Jefferson University Hospital, Philadelphia, Pennsylvania

Status

Withdrawn

Address

Thomas Jefferson University Hospital

Philadelphia, Pennsylvania, 19107

UPMC-Shadyside Hospital, Pittsburgh, Pennsylvania

Status

Active, not recruiting

Address

UPMC-Shadyside Hospital

Pittsburgh, Pennsylvania, 15232

Geisinger Cancer Services-Pottsville, Pottsville, Pennsylvania

Status

Recruiting

Address

Geisinger Cancer Services-Pottsville

Pottsville, Pennsylvania, 17901

Site Contact

Site Public Contact

[email protected]

800-275-6401

Asplundh Cancer Pavilion, Willow Grove, Pennsylvania

Status

Withdrawn

Address

Asplundh Cancer Pavilion

Willow Grove, Pennsylvania, 19090

Lankenau Medical Center, Wynnewood, Pennsylvania

Status

Recruiting

Address

Lankenau Medical Center

Wynnewood, Pennsylvania, 19096

Site Contact

Site Public Contact

[email protected]

484-476-2649

UPMC Memorial, York, Pennsylvania

Status

Active, not recruiting

Address

UPMC Memorial

York, Pennsylvania, 17408

Medical University of South Carolina, Charleston, South Carolina

Status

Recruiting

Address

Medical University of South Carolina

Charleston, South Carolina, 29425

Site Contact

Site Public Contact

[email protected]

843-792-9321

Prisma Health Cancer Institute - Faris, Greenville, South Carolina

Status

Recruiting

Address

Prisma Health Cancer Institute - Faris

Greenville, South Carolina, 29605

Site Contact

Site Public Contact

864-241-6251

Covenant Medical Center-Lakeside, Lubbock, Texas

Status

Recruiting

Address

Covenant Medical Center-Lakeside

Lubbock, Texas, 79410

Site Contact

Site Public Contact

[email protected]

806-725-8000

Richmond, Virginia

Status

Active, not recruiting

Address

Virginia Commonwealth University/Massey Cancer Center

Richmond, Virginia, 23298

West Virginia University Healthcare, Morgantown, West Virginia

Status

Active, not recruiting

Address

West Virginia University Healthcare

Morgantown, West Virginia, 26506

Madison, Wisconsin

Status

Recruiting

Address

University of Wisconsin Carbone Cancer Center

Madison, Wisconsin, 53792

Site Contact

Site Public Contact

800-622-8922

Froedtert Menomonee Falls Hospital, Menomonee Falls, Wisconsin

Status

Recruiting

Address

Froedtert Menomonee Falls Hospital

Menomonee Falls, Wisconsin, 53051

Site Contact

Site Public Contact

262-257-5100

Medical College of Wisconsin, Milwaukee, Wisconsin

Status

Recruiting

Address

Medical College of Wisconsin

Milwaukee, Wisconsin, 53226

Site Contact

Site Public Contact

414-805-3666

Drexel Town Square Health Center, Oak Creek, Wisconsin

Status

Recruiting

Address

Drexel Town Square Health Center

Oak Creek, Wisconsin, 53154

Site Contact

Site Public Contact

414-805-0505

West Bend, Wisconsin

Status

Recruiting

Address

Froedtert West Bend Hospital/Kraemer Cancer Center

West Bend, Wisconsin, 53095

Site Contact

Site Public Contact

414-805-0505